37.38MMarket Cap-367P/E (TTM)
0.519High0.490Low172.97KVolume0.490Open0.492Pre Close88.14KTurnover0.36%Turnover RatioLossP/E (Static)72.19MShares2.36052wk High1.33P/B25.22MFloat Cap0.29652wk Low--Dividend TTM48.70MShs Float16.410Historical High--Div YieldTTM5.96%Amplitude0.296Historical Low0.509Avg Price1Lot Size
Beyond Air Stock Forum
Strengthened balance sheet is expected to provide sufficient cash runway through June 2026
Completed a $20.6 million private placement offering with multiple healthcare-focused institutional funds and Company insiders
Retired $17.5 million in debt from Avenue Capital and entered into a $11.5 million loan agreement with an insider-led investor group
Conference call scheduled for 4:30 p.m. ET today...
Beyond Cancer Presents Promising Preclinical Data on Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Beyond Cancer presented promising preclinical data on Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) therapy at SITC 2024. The study showed that LV UNO combined with anti-rPD-L1 doubled tumor growth inhibition and improved survival in MAT B III tumor-bearing rats compared t...
Beyond Cancer to Present Preclinical Data of Ultra-High Concentration Nitric Oxide (UNO) Low Volume Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Beyond Cancer, , a clinical stage biotechnology company, has been selected to present two poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024. The event is scheduled for November 6-10 at the George R. Brown Convention Center in Houston, Texas. The ...
No comment yet